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ABSTRACT 
 
Malaria is a huge global health threat, causing thousands of deaths and suffering every year, worldwide. 
Although there are some effective drugs available at present, the parasite often acquires resistance in 
the face of drug pressure. In order to choose the most efficient strategy to fight against this disease, it is 
imperative that we understand the basic biology of its causative agent Plasmodium.  
 
Plasmodium species express a number of proteases that have important roles in fundamental processes 
and, therefore, are potential drug targets. A number of serine proteases belonging to the subtilisin-like 
family, also named subtilases, have been identified in apicomplexan parasites like Toxoplasma, 
Neospora and Plasmodium. The Plasmodium genome has three subtilisin-like proteases. It has been 
shown in Plasmodium falciparum that the subtilisin-like proteases 1 (PfSub1) and 2 (PfSub2) have 
important roles in the invasion and egress of parasites from erythrocytes. However, little is known about 
subtilisin-like protease 3 (Sub3) in Plasmodium species. In this study, we used gene targeting to disrupt 
the sub3 gene in the rodent malaria parasite Plasmodium berghei ANKA and analyzed the effect of the 
deletion in the life cycle of the mutant.  
 
When mosquitoes were infected with the sub3 deletion mutants, we found no differences in the number 
of oocysts or salivary gland sporozoites compared to controls.  We performed in vitro and in vivo 
experiments to further study the ability of the deletion mutants to establish infection in the mammalian 
host. Results show that recombinant parasites are able to normally infect and develop in the liver and 
blood. In consequence, deletion of sub3 gene did not impair or significantly affected parasite 
development in its natural hosts.   
 
       – malaria, Plasmodium berghei, proteases, subtilisin-like protease 3, sub3 – 
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RESUMO 
 
Estima-se que em 2009, metade da população mundial se encontrava em risco de contrair malária. 
Recentes estatísticas mostram que, no mesmo ano, aproximadamente 800 000 seres humanos 
morreram. Esta é uma doença que atinge maioritariamente os países em desenvolvimento do 
continente africano, asiático e sul-americano.  
A malária, ou paludismo, é causada por parasitas do género Plasmodium, pertencente ao filo 
Apicomplexa. A este filo pertencem vários parasitas eucariotas unicelulares com importante relevância 
médica, como é o caso dos géneros Crisptosporidium e Toxoplasma.  
As espécies de Plasmodium apresentam um ciclo de vida complexo que requer dois hospedeiros: o 
mamífero, onde apenas ocorre reprodução assexuada, e o vector invertebrado, onde adicionalmente há 
recombinação genética. O ciclo inicia-se quando o mosquito fêmea Anopheles tem uma refeição de 
sangue, ao picar a pele do hospedeiro, e inocula na derme parasitas sob a forma de esporozoítos. 
Seguidamente, os esporozoítos entram na corrente sanguínea, chegando ao fígado onde iniciam o seu 
desenvolvimento nos hepatócitos. Apesar de esta fase ser assintomática, os parasitas multiplicam-se 
assexuadamente originando milhares de parasitas denominados merozoítos que, quando libertados no 
sangue, são capazes de invadir eritrócitos. Nos eritrócitos o parasita inicia a fase seguinte do seu 
desenvolvimento, passando por sucessivos estádios de maturação que culminam na libertação de novos 
merozoítos. Ao fim de vários ciclos de multiplicação no sangue, alguns merozoítos diferenciam-se em 
formas sexuais – os gametócitos –, que são ingeridos durante a refeição de sangue do mosquito dando 
início à fase sexuada do ciclo de vida. Após recombinação no vector, o parasita começa uma nova fase 
de reprodução assexuada originando milhares de esporozoítos, que migram do intestino para as 
glândulas salivares do mosquito. Numa próxima refeição, os esporozoítos são inoculados na pele do 
hospedeito dando início a um novo ciclo. 
A elevada morbilidade e mortalidade da malária torna a sua erradicação uma das principais prioridades 
da Organização Mundial de Saúde. Durante décadas, têm sido feitos inúmeros esforços com o intuito de 
erradicar a doença. Há cinquenta anos atrás, a malária foi eliminada em muitas áreas do planeta, 
através do uso de drogas como a cloroquina. No entanto, devido ao desenvolvimento de resistência por 
parte do parasita, a incidência da doença aumentou novamente. Recentemente têm sido utilizadas 
novas e eficientes drogas como a artemisina. Infelizmente, foram identificados recentemente casos de 
resistência à artemisina. Se este fenómeno se alastrar, as consequências podem ser devastadoras e, 
por essa razão, é extremamente importante que novos compostos e alvos sejam descobertos.  
As proteases do parasita da malária apresentam um enorme potencial como alvos de novos compostos 
devido ao papel crucial que desempenham em várias fases fundamentais à continuidade do ciclo de 
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vida. As subtilases pertencem à grande família das proteases de serina e caracterizam-se pela ordem 
onde se localizam os resíduos que compõe o seu centro activo: Asp – His – Ser. Em P. falciparum são 
conhecidas três subtilases: subtilase 1, 2 e 3. Enquanto que Sub1 está envolvida na via proteolítica que 
induz a saída dos merozoítos dos eritrócitos, a Sub2 está implicada na invasão dos mesmos. O presente 
trabalho focou-se particularmente numa protease sobre a qual não existem quaisquer estudos 
funcionais – a subtilase 3 (Sub3). 
Para melhor compreender o papel da Sub3 no parasita, o nosso trabalho foi dividido em duas etapas: o 
estudo do padrão de expressão do gene sub3 e a caracterização de um parasita com uma deleção no 
mesmo gene. Todas as experiências foram realizadas em P.berghei, um parasita de roedores 
reconhecido como um modelo válido para a investigação experimental em malária.  
A expressão de sub3 foi analisada em esporozoítos no intestino e glândulas salivares do mosquito, bem 
como em parasitas presentes no sangue de ratinhos infectados. A presença de RNA mensageiro de 
sub3 foi detectada em esporozoítos no intestino do mosquito, com resultados reprodutíveis em todas as 
experiências realizadas. No entanto, os resultados obtidos nos restantes estádios analisados não foram 
igualmente consistentes.   
O parasita mutante, gerado por recombinação homóloga, contém uma deleção no gene que codifica a 
subtilase 3. A região delectada no locus recombinante inclui o codão de iniciação da tradução, os 
resíduos de histidina e serina do centro activo e parte da região codificante.  
O primeiro passo na análise da população de mutantes, também denominados parasitas sub3Δ, foi a 
infecção de mosquitos Anopheles fêmea. Um defeito nesta fase do ciclo pode significar um bloqueio na 
transmissão do parasita. Contudo, os vários ensaios experimentais mostraram que o desenvolvimento 
do parasita recombinante ocorre de forma normal no vector, culminando com a presença de 
esporozoítos nas glândulas salivares do mosquito. O sucesso da infecção no vector prova, ainda, que os 
gametócitos previamente ingeridos pelo mosquito estão funcionalmente activos.  
Em seguida, avaliámos a mobilidade dos esporozoítos sub3Δ. Se esta propriedade for afectada, os 
parasitas serão menos eficientes a migrar do local de inoculação para os vasos sanguíneos originando, 
potencialmente, um parasita com menor probabilidade de continuar o seu percurso. Para analisar a 
capacidade de locomoção dos mutantes realizámos experiências in vitro e in vivo. Quando depositados 
numa superfície de vidro, os esporozoítos recombinantes revelam uma ligeira diminuição na sua 
mobilidade. Contudo, quando em contacto com uma monocamada de hepatócitos, os esporozoítos 
sub3Δ atravessam as células com igual eficiência relativamente aos parasitas controlo. Um resultado 
similar foi obtido in vivo: após inoculação na derme de ratinhos, os esporozoítos sub3Δ chegam ao 
fígado com sucesso e sem atraso relativamente aos controlos. Em conjunto, os resultados indicam que a 
via natural de infecção do parasita não foi afectada. 
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Posteriormente analisámos a fase hepática do ciclo de vida. Tal como foi descrito anteriormente para o 
estudo da locomoção, o desenvolvimento do parasita sub3Δ no fígado foi analisado in vitro e in vivo. 
Ambos os ensaios demonstram que a multiplicação de parasitas sub3Δ durante a fase hepática ocorre 
tal como é esperado em parasitas wild type. 
Em suma, os resultados apresentados mostram que apesar de RNA mensageiro de sub3 ser detectado 
nos parasitas, a deleção de sub3 não afecta o progresso do parasita recombinante ao longo do ciclo de 
vida. Curiosamente, ao contrário do observado para as subtilases 1 e 2, não foram detectadas 
diferenças fenótipicas, nas fases do desenvolvimento analisadas, entre o parasita mutante gerado para 
estudar a subtilase 3 e os parasitas wild type, tornando difícil compreender o papel desta protease no 
parasita.  
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INTRODUCTION 
 
Malaria – Prevalence of the disease and Lifecycle of its causative agent 
In 2009, about 3.3 billion people - half of the world's population - were at risk of malaria, making it the 
world's most deadly parasitic and vector borne disease. Every year, it leads to about 250 million known 
cases and, in 2009 alone, it was responsible for nearly 800 thousand deaths, killing more under-5-year-
olds than any other disease (WHO, 2010). Malaria affects mainly regions of Africa, Asia and South 
America (Figure 1).  
 
Figure 1. Global map of malaria endemic countries highlighted in dark grey (WHO, 2010).  
 
Malaria is caused by parasites of the genus Plasmodium. In humans, it is caused mainly by four species: 
P. malariae, P. ovale, P.vivax and P. falciparum,  with the last being responsible for the most severe form 
of the disease. Plasmodium species belong to the ubiquitous and highly successful phylum Apicomplex 
which contains other parasites of major medical importance, such as Toxoplasma and Cryptosporidium.   
 
Plasmodium spp has evolved a complex life cycle with essential developmental stages in both the 
anopheline mosquito vector and the vertebrate host (Figure 2). Infection is initiated when an infected 
mosquito containing Plasmodium sporozoites in its salivary glands bites a mammalian host while it 
probes for blood. During this process sporozoites are injected into the dermis, where most of them will 
move through until, eventually, contact blood vessels and enter the circulatory system (Amino et al., 
2008).  
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Once in the blood, sporozoites are rapidly sequestered in the liver sinusoids which they have to cross, 
primarily through Kupffer cells, in order to reach and invade hepatocytes (Murray et al., 2005; Frevert et 
al., 2005). Sporozoites do not invade the first hepatocyte they encounter. Instead, they migrate through 
several hepatocytes before invading a final one in which a parasitophorous vacuole (PV) is formed (Mota 
et al., 2001). Following productive invasion, each sporozoite differentiates into an exoerythrocytic form 
(EEF) and multiplies by schizogony inside the hepatocyte, thereby generating thousands of new parasites 
that are now capable of infecting erythrocytes – the merozoites (Aly et al., 2009; Sturm et al., 2006). 
When EEF development is completed merozoite-filled vesicles, the merosomes, are formed and released 
into the liver sinusoid (Sturm et al., 2006). Merosomes will then enter the bloodstream and finally 
rupture and release the first generation of merozoites (Baer et al., 2007).  
 
Figure 2. Life cycle of Plasmodium. Infected female Anopheles mosquito injects sporozoites while it takes a blood 
meal (1).  Sporozoites reach the liver (2) and multiply asexually generating merozoites (3) which are then released 
in vesicles and reach the blood (4). In the bloodstream, the merozoites invade erythrocytes and multiply until they 
egress only to invade a new cell (5). Some merozoites develop into sexual forms, called gametocytes that circulate 
in the bloodstream (6). When a mosquito bites an infected human, it ingests gametocytes which further develop 
into mature sex cells named gametes (7). A diploid zygote is formed by fusion of a female gamete with a male 
gamete. The zygote transforms in to a motile ookinete that burrow through the mosquito's midgut wall and form 
oocysts (8). Inside the oocysts, thousands of active sporozoites develop eventually bursting it and releasing all the 
parasites in the hemolymph (9). Eventually sporozoites migrate to the salivary glands and a new cycle begins when 
the mosquito bites the next host (10). Adapted from Baer et al., PloS Pathogen 2007 (11)e171. 
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Plasmodium, as other related apicomplexan parasites such as Babesia, have the unusual capacity to 
rapidly invade red blood cells (RBC) – erythrocyte invasion by merozoites occurs within seconds and by 
simultaneous formation of a PV. Once invasion is completed the merozoite transforms into a ring stage, 
which is characterized by a large digestive vacuole, where hemoglobin digestion results into the 
formation of the malaria pigment, hemozoin. The ring stage develops into a trophozoite that multiplies by 
schizogony originating an erythrocyte schizont, which ultimately generates newly formed merozoites that, 
when fully developed, egress from the RBC and initiate a new cycle (reviewed in Silvie et al., 2008). After 
several cycles of multiplication in the blood, some merozoites will differentiate in gametocytes. The 
factors that initiate and regulate the formation of gametocytes are not yet well understood. 
Ingestion of gametocytes by a mosquito during a blood meal initiates the cycle in the invertebrate host 
where both asexual and sexual reproduction take place. Ingestion of gametocytes activates the 
formation of gametes – gametogenesis - in the mosquito midgut lumen (Bilker et al., 1997, 1998). This 
process generates the female and male gametes that will fuse to form the zygote, the only diploid form in 
the life cycle of Plasmodium. Soon after zygote formation, meiose takes place and genetic recombination 
occurs. The spherical zygote transforms into an ookinete, an elongated motile cell that uses motility to 
penetrate and later traverse the mosquito midgut epithelium. The migration through epithelial cells 
activates the ookinete to switch to a sessile mode and initiate its transformation into an oocyst, a 
process that takes approximately 10-12 days. In the oocyst, sporoblasts are formed within which, mitotic 
divisions take place and, consequently, sporozoite formation begins. The budding of sporozoites from the 
sporoblasts is asynchronous and happens prior to sporozoite egress from the oocyst, culminating in 
release of parasites into the mosquito circulatory system – the hemolymph. Parasite ligands recognize 
specific host receptors that allow the sporozoite to adhere to the basal lamina of the salivary gland but 
not to any other mosquito tissue (reviewed in Aly et al., 2009). Parasites will then invade the salivary 
glands and complete their development into sporozoites that are fully capable of starting a new cycle 
when injected in the mammalian host upon a mosquito blood meal.  
 
 
Malaria – The need to discover novel drug targets  
When merozoites egress from the erythrocyte, malaria symptoms begin: the paroxysms, consisting of 
chills, fever and malarial rigors. It may remain relatively mild or progress to severe attacks with hours of 
sweating, chills, persistent high fever and exhaustion (Murray et al., 2005). If not treated, P. falciparum 
malaria can evolve in to a severe and, maybe fatal, disease called cerebral malaria. The fact that 
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infection can cause serious complications in humans together with the high prevalence of malaria, 
makes its eradication one of today's top priorities of the World Health Organization.  
Fifty years ago, malaria had been eliminated from many areas of the world through treatment with the 
fast-acting and inexpensive drugs chloroquine and pyrimethamine-sulphadoxine (Greenwood et al., 
2008). Unfortunately, the global spread of drug resistance resulted, by the 1980's, in a resurgence of 
disease incidence and mortality. The introduction of new drugs, notably the artemisinin-based 
combination therapies, reversed that trend (Eastman and Fidock, 2009). However, recent reports 
suggest that resistance to derivatives of artemisinin is now emerging (Dondorp et al., 2009; Noedl et al., 
2008; White 2008). These observations have triggered a concerted search for new drugs that could be 
deployed if artemisinin resistance were to spread.  
Besides screening for new drugs that will interfere with transmission or the onset of the disease, we 
must expand our understanding of the basic biology of Plasmodium species. An intrinsic knowledge of 
parasite-specific processes can be exploited to discover new drug targets or adopt different intervention 
strategies. With this intention, we focused our efforts on the study and characterization of parasite 
proteases, namely, the subtilisin-like protease 3.  
 
Plasmodium subtilisin-like proteases  
Subtilisin-like proteases, or simply subtilases, are an ancient group of serine proteases that are widely 
dispersed throughout evolution. They are functionally diverse but, in most cases, are secreted to function 
either within the secretory system or extracellularly. Subtilases are distinguished from other serine 
proteases by the order in which their catalytic triad residues are arranged: Asp – His – Ser. (Siezen and 
Leunissen, 1987; Rawlings et al., 2002). 
 
Subtilases have been characterized in several Apicomplexan parasites like Toxoplasma, Neospora and 
Plasmodium (Miller et al., 2001, 2003; Louie and Conrad, 1999). Currently, there are three different 
subtilases known to be present in P. falciparum: Pf subtilase (PfSub) 1, 2 and 3.  Orthologues of all three 
genes are evident in the available genomic sequence data from a number of other Plasmodium species. 
However, all experimental work to date on Plasmodium subtilases has focused on the P.falciparum and 
P.berghei enzymes. P.berghei is a specie that infects rodents and is often used as an animal model to 
study experimental malaria. In this section, we briefly describe the current knowledge on each of the 
Plasmodium subtilases.  
 
Work in P. falciparum revealed details of a proteolytic pathway in which egress of merozoites from the 
erythrocyte is triggered by the discharge of PfSub1 into the PV lumen (Yeoh et al., 2007; Blackman et al., 
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1998). There, PfSub1 directly mediates the proteolytic maturation of a family of abundant, soluble, 
papain-like putative proteases called the serine-rich antigen (SERA) family, previously implicated in 
egress (Aly et al., 2005; Pang et al., 1999). It has been subsequently shown that PfSub1 is also required 
for merozoite maturation. Upon its release into the PV just before egress, PfSub1 additionally carries out 
the well described primary proteolytic processing of the most abundant merozoite surface component, 
an essential, glycolipid-anchored, heteromultimeric protein complex called MSP1/6/7 (Koussis et al., 
2009). This complex seems to be essential for an initial low-afinity binding of the merozoite to the 
surface of erythrocytes prior to invasion. These findings identify PfSub1 as a multifunctional enzyme that 
plays a major role both in the egress and invasion of erythrocytes.  
 
In 2005, Harris and colleagues discovered that PfSub2, is responsible for the shedding of MSP1 and 
AMA-1.  As previously mentioned MSP1 complex is required for initial binding to the erythrocyte. AMA-1 is 
thought to be involved in the subsequent interactions between host cell surface and merozoite, 
mediating re-orientation and junction formation. PfSub2 is stored until rupture of the schizont and it is 
successively released onto the parasite surface where it proteolitically cleaves the MSP1 complex and 
AMA1. The proteolytic maturation of these proteins are conserved among Plasmodium species and 
essential for RBC invasion (Blackman et al., 1991a; 1996; Howell et al., 2001).  Therefore, Subtilase 2 is 
implicated in the success of erythrocyte invasion by merozoites. 
 
The presence of a P. falciparum gene encoding a third subtilase was only revealed during the acquisition 
of the genome sequence. The predicted PfSub3 primary sequence features a most unusual HGHGTFIAG 
motif flanking the predicted active site His residue. Microarray studies have indicated that the 
P.falciparum gene is transcribed in blood stages and sporozoites (Le Roch et al., 2003). However, mass 
spectrometry studies only detected expression in the sporozoite (Florens et al., 2005) There are no 
published reports on functional characterization of Sub3 from any Plasmodium species. However, if this 
subtilase is indeed expressed as an active enzyme, the unusual motif may play a role in substrate 
recognition and it is precisely this kind of unusual sequence signature that may provide distinctive 
specificity characteristics that can be exploited in the design of selective drugs.  
 
The main goal of this study was to get a better understanding of subtilase 3. In order to do this we used 
gene targeting to disrupt subtilisin-like protease 3 gene in the rodent malaria parasite P.berghei and 
characterized the mutant parasites.  
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MATERIALS AND METHODS 
 
Construction of plasmid sub3Δ 
Sequences of homology 
A 726bp fragment of sub3 (accession number PBANKA_110680) 5’ untranslated region (UTR) 
sequence was amplified using primer set 1 as HindIII/PstI fragment from genomic DNA of P. 
berghei ANKA strain. This sequence is located 96 bp upstream the start codon of sub3 coding 
sequence. A second fragment of 668bp KpnI/EcoRI was amplified using primer set 2. This 
sequence is located within the coding sequence 26bp upstream the stop codon. 
 
Polimerase Chain Reaction (PCR) 
Fragments used to make the transfection plasmid were amplified from 100ng of genomic DNA of 
P.berghei ANKA strain by PCR using Pfu DNA polymerase. Primer sequences and their targets are 
represented schematically  in (Annex IV and V). All PCR products mentioned in this thesis were 
run in an agarose gel in TAE 1X, stained in ethidium bromide (EtBr), destained in TAE 1X and 
visualized on a UV Transiluminator. The size of amplified products was determined by 
comparison with a DNA ruler (HiLo DNA Marker, Bionexus). 
 
Cloning and purification of PCR Products 
Each amplified fragment was cloned in pCR4-TOPO vector (Invitrogen) and E.coli TOP-10 
competent cells were transformed with the plasmid. DNA was extracted from 3mL of transformed 
bacteria grown overnight in Luria-Bertani medium with 100µg\mL of ampicilin. Presence of 
fragments with the correct size was tested by double digestion of the DNA. DNA extracted from 
bacteria transformed with the upstream fragment was digested with HindIII and PstI (New 
England BioLabs). DNA from bacteria transformed with the downstream fragment was digested 
with KpnI and EcoRI (New England BioLabs). Enzymatic digestions were performed for 2h at 37ºC 
using 1U of each enzyme in appropriate provided buffers. The digested fragments were 
separated in a 1.5% agarose and extracted using Qiagen gel extraction kit.  
 
Insertion of fragments in the pDEF-hDHFR plasmid 
pDEF-hDHFR (Annex I) was digested with HindIII as previously described and dephosphorilated 
with CIP phosphatase for 1h at 37ºC. Following this the digested upstream fragment was inserted 
upstream the hDHFR cassette through ligation with T4 DNA Ligase (Fermentas) performed 
overnight at room temperature (RT) using a proportion of vector:insert of 1:4. After 
transformation of E.coli XL-10 Gold competent cells and confirmation of insertion of the fragment 
by double digestion, the resultant plasmid was digested with KpnI and the digested downstream 
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fragment was inserted downstream the hDHFR cassette using the same methodology described 
above. The correct generation of the plasmid sub3Δ (Annex II) was confirmed by sequencing.  
 
 
Generation of sub3Δ mutant parasites 
Preparation of the sub3Δ plasmid 
The transfection plasmid was isolated from E. coli XL-10®Gold ultracompetent cells using Qiagen 
Maxiprep (Qiagen), starting from 250mL of bacteria grown overnight in standard Luria-Bertani 
medium with 100µg\mL ampicilin. The DNA pellet was resuspended in 350 µl of 10mM Tris–1 
mM EDTA (pH 8.0) at a final concentration of 1 µg/µl. In order to excise the fragment for 
transfection, 78µg of the final construct was digested for 4h at 37ºC with restriction enzymes 
HindIII and EcoRI (New England BioLabs) in a final volume of 100 µl. To guarantee complete 
digestion and prevent the presence of circular autonomously replicating plasmids, 2 µl of each 
sample was analyzed by 0.7% agarose gel electrophoresis after 2h of digestion. The 3029bp 
linearized fragment was purified by ethanol precipitation and stored at -20ºC. 
 
Preparation of recipient parasites 
One male Wistar rat (Taconic farms Inc) was injected intraperitonally (i.p.). with infected frozen 
stocks of P. berghei strain ANKA GFP 507 clone 1, which expresses GFP under the control of the 
ef1a promoter. When parasitemia reached 3% on day 3 post infection (p.i.), blood was collected 
by cardiac puncture and cultured in vitro with 141.25mL of RPMI (Sigma-Aldrich), 35mL of Fetal 
Calf Serum (Thermo Fisher Scientific), 1.25mL of Gentamycin (Sigma-Aldrich) for each culture. 
The cultures were incubated at 37ºC, 5%CO2, for 20h at 77 rpm. 
 
Electroporation of schizonts with linearized DNA 
Parasite schizonts were collected and purified by gradient centrifugation using a 55% 
Nycodenz\1XPBS solution. After centrifugation the brown layer of schizonts was collected and the 
number of schizonts was determined using a hemocytometer. Recombinant parasites were 
generated using the program U33 of the Amaxa Nucleofector device (Lonza Walkersville Inc). 107  
schizonts were electroporated with 12µg of the linearized fragment (Janse et al., 2006). 
Immediately after transfection, schizonts were injected intravenously (tail vein) in a female Swiss 
Webster mice. Each set of electroporated schizonts was injected intravenously (i.v.) in one female 
naïve mouse.  
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Selection of recombinant parasites 
Drug Selection 
The selective cassette hDHFR confers resistance to the drug pyrimethamine. 24h after 
transfection parasites were put under pyrimethamine pressure by providing the drug to the 
infected mice in their drinking water. Pyrimethamine was first dissolved in DMSO (7 mg/mL) and 
subsequently diluted 100X in drinking water at a 4.0 pH. During treatment parasitemia was 
monitored daily and after 5 days of treatment pyrimethamine pressure was removed. When 
parasitemia reached 4-5% blood was collected by performing cardiac puncture on anesthetized 
infected mice.  
 
Extracting parasite genomic DNA from infected whole blood 
Approximately 1.3mL of whole blood collected from each mouse was purified in order to obtain 
RBCs only. A two-step purification protocol was performed by using a column filled with glass 
beads (Sigma) followed by purification through a column filled with cellulose (Whatman). 
Columns were washed with 1X PBS until 25mL were collected from the second column. After 
centrifugation at 3000rpm for 7minutes (min) a pellet of RBCs was obtained and lysed by adding 
25mL of 0.2% saponin (Sigma) in 1XPBS and incubated at RT for 5min. After centrifugation at 
3000 rpm for 15min parasite pellet was collected and genomic DNA extracted using QIAamp 
DNA blood mini kit (Qiagen).  
 
Presence of recombinant parasites 
Presence of mutants was confirmed by detection of the hDHFR cassette. PCR was performed 
using DNA polymerase and primer set 3 in order to amplify a 482bp fragment within the hDHFR 
cassette. In each PCR reaction 100ng of parasite genomic DNA previously extracted was used. 
PCR product was run in a 2.5% agarose gel.  
 
 
Cloning recombinant parasites in mice 
Proportion of mutants present in the blood of the two mice injected with electroporated schizonts was 
determined by PCR using primer set 4. PCR product was run in a 0.7% agarose gel. Frozen blood from 
the mouse infected with the transfected population of parasites was inoculated i.v. in a naïve Swiss 
Webster donor mouse. At 0.93% parasitemia infected blood was collected by performing cardiac 
puncture in the infected mouse. The concentration of parasites was determined using a hemocytometer. 
The blood was serial diluted in order to inject 2 parasites in 200µL of DMEM in each mouse (Menard and 
Janse, 1997). Mice were monitored daily by blood smear and on day 10 p.i. positive mice were sacrificed 
and parasite genomic DNA was extracted as previously described. The presence of clones was tested by 
PCR amplification of a hDHFR fragment using primer set 3. The presence of WT parasites was tested by 
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PCR using primer set 5 which amplified a 623bp fragment in the 5' end of the sub3 coding sequence. 
PCR product obtained using primer set 5 was run in a 2.5% agarose gel.  
 
 
Integration of transfected fragment in sub3Δ originated clones 
Integration of the transfected DNA at the correct location was verified by PCR using 100ng of parasite 
genomic DNA. 5' integration was tested using primer set 6 which amplifies a 1965bp fragment. Primer 
set 7 tested for 3' integration and it amplifies a 982bp fragment. Primer set 8 was used to test the 
presence of episomal plasmid and it amplified a 1225bp. All PCR products were run in a 1.5% agarose 
gel..  
 
 
Detection of parasites in the blood  
A drop of blood was collected from the tail of a mouse and placed on one end of a microscope slide. A 
blood film was made by using a spreader slide to disperse the blood evenly over the slide's length. The 
slide was left to air dry for 2min, after which the blood was fixed by immersing it briefly in 100% 
Methanol (Sigma). After fixation the slide was stained for 10 min in 1:5 Giemsa solution in water. The 
slide was observed under a light microscope at a 100X magnitude. Parasitemia was determined by 
counting the number of infected RBCs (iRBCs) in a minimum total of 1000 RBCs.  
 
 
Mosquito infection 
Preparation of mice  
A frozen vial of infected blood was inoculated by i.p. injection in one Swiss Webster naïve donor 
mouse. Parasitemia was monitored daily and at 4-5% parasitemia blood was collected from the 
mouse. The infected blood was diluted in DMEM to 1% parasitemia and 200µL of this solution 
was injected i.p. in each Swiss Webster mouse. A group of five mice were injected per donor 
mouse. The injected animals were monitored daily and on day 3-4 p.i. mice showed a high 
percentage of mature gametocytes and, therefore, were considered ready for mosquito feeding.  
 
Mosquitoes Infection 
Three- to five-day old Anopheles stephensi mosquitoes were starved for a minimum period of two 
hours prior to feeding. After starving, mosquitoes fed on anaesthetized infected Swiss Webster 
mice for 15 min. 24h later after the first feeding mosquitoes had a similar second blood meal. 
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Mosquito dissection 
Midguts  
The average number of oocysts per midgut was determined by dissection of 10-15 female 
mosquitoes on day 10 p.i.. Harvested midguts were observed under a fluorescence microscope 
at  10x magnification. The average number of midgut sporozoites was determined by dissection 
of 10-15 female mosquitoes on day 12-15p.i.. Collected midguts were pooled and homogenized. 
Number of sporozoites was determined using a Neubauer chamber (average of sporozoites per 
quadrant x 104 x dilution factor), that was previously maintained in a moist chamber for 10min. 
 
Salivary glands 
On day 18-21 p.i. salivary glands of mosquitoes were dissected, pooled and homogenized. 
Released sporozoites were counted as described above 
 
.  
Gliding motility assay 
Glass eight-chambered Lab-Tek wells were coated with 10 μg/mL of monoclonal antibody 3D11 in 1x 
PBS overnight at 4ºC. After washing wells 3 times with PBS, 2 x 104 sporozoites were added to each well 
in DMEM–3%BSA medium and incubated for 1h at 37ºC. The medium was then removed and the wells 
were fixed with 4% PFA for 30min at 37ºC. After fixation, wells were washed and blocked with PBS–1% 
BSA for 1h at 37ºC. To visualize the trails, the wells were incubated with 10 μg/mL biotinylated mAb 
3D11 followed by streptavidin-fluorescein isothiocyanate (1:100 dilution; Amersham Pharmacia, GE 
Healthcare, Piscataway, NJ). Trails were observed under a fluorescence microscope at 40x magnification. 
 
 
In vitro sporozoite traversal assay 
3 x 105 HepG2 cells were plated on previously collagen type I coated coverslips. 16-18h later 2,5 x104 
sporozoites dissected in 1%BSA\DMEM were added to the cells in the presence of 1mg\mL TOTO-1 
(Invitrogen) for 1h at 37ºC. Cells were washed with DMEM and fixed with 4%PFA for 30min at 37ºC. The 
number of TOTO-1 positive cells in 20 fields was counted under a fluorescence microscope at 40x 
magnification. 
 
 
In vitro development assay  
HepG2 cells were seeded on previously collagen type I coated coverslips and allowed to grow until sub-
confluent (12-16h). Salivary glands were dissected in 10X Pen\Strep DMEM and 5 x 104 sporozoites 
were added to each coverslip. After an incubation period of 24h at 37ºC  and 5%CO2, cells were fixed 
with 4% PFA for 1 hour at 37ºC. Parasites were stained with mAb 2E6, 10ug\mL, followed by anti-Mouse 
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IgG conjugated to FITC (1:100). Incubation with antibodies was performed at 37ºC for 1h. DNA was 
stained by incubation of cells with Hoechst 33258 2ug\mL for 3 min. The number of stained EEFs per 
coverslip was counted under a fluorescence microscope at 40x magnification. 
 
 
Determination of prepatent period  
After salivary gland dissection C57BL/6 mice were injected i.v. with the indicated number of sporozoites 
and the onset of blood stage infection was determined by daily observation of Giemsa-stained blood 
smears, beginning on day 3p.i. until day 7p.i. 
 
 
Quantification of parasite burden in the liver by qPCR 
Each Swiss Webster and C57BL/6 mouse was injected i.d. or i.v., respectively, with 104 sporozoites 
dissected from salivary glands of infected female mosquitoes. 38 h.p.i. mice were sacrificed and livers 
were harvested, washed in 1X PBS and weighted. 1mL of TriReagent®  was added per 10g of tissue and 
livers were homogeneized. After incubation at RT for 15min, 1mL of the homogenate was used to extract 
total RNA following the product protocol. Reverse transcription was performed with 2µg of RNA using the 
Applied Biosystems high capacity RNA to cDNA kit. Obtained cDNA was used to determine liver parasite 
burden which was quantified by qPCR as previously outlined (Bruña-Romero et al., 2001) using primer 
set 9 which recognizes P.berghei-specific sequences within 18S rRNA (Kumar et al., 2004). 10-fold 
dilutions of a plasmid construct containing the P.berghei 18S rRNA gene were used to create a standard 
curve.  
 
 
Detection of sub3 mRNA transcripts 
Sample collection 
2.5 x 106 P.berghei ANKA sporozoites were collected from midguts harvested from a minimum 
number of 50 infected mosquitoes on day 12 p.i.; 1.5x106   P.berghei ANKA sporozoites were 
collected from dissected salivary glands of a minimum number of 100 infected mosquitoes on 
day 18 p.i.; P.berghei ANKA mixed blood stages were collected after lysis of RBCs collected and 
purified from infected whole blood harvested from two infected Swiss Webster mice when 
parasitemia was above 6%. 
 
RNA extraction and transcripts detection 
Collected samples were incubated for 5min at 37ºC in pre-warmed TriReagent®. After RNA 
extraction and precipitation following the product protocol, the RNA was treated with DNaseI 
(Invitrogen) for 15min at RT. Enzyme was inactivated with 25mM EDTA and RNA was precipitated 
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with 3M NaOAc and 100% EtOH. cDNA was obtained by reverse transcription (Applied Biosystems 
high capacity RNA to cDNA kit) and used to perform PCRs. Primer set 5 was used to detect sub3 
transcripts and primer set 10 was used to amplify a 260bp fragment in the hsp70 coding 
sequence. PCR products were run in a 2.5% agarose gel.  
 
 
Cells  
HepG2 cells (American Type Culture Collection), a human hepatoma cell line, were maintained in DMEM 
(Gibco) supplemented with 10% fetal calf serum and 1mM glutamine at 37ºC in 5%CO2. 
 
 
Mice 
Four to five-week old female Swiss Webster Mice and C57BL/6 mice (Taconic) were used in the 
described assays. All experiments using animals were approved by the Institutional Animal Care and 
Committee at the New York University School of Medicine.  
 
 
Antibodies 
mAb 3D11 was used for motility assays and it is directed against the repeat region of P. berghei CSP 
(Yoshida et al.,1980). For the development assays we used mAb 2E6, which is directed against 
Plasmodium Hsp70 (Tsuji et al., 1994).  
 
 
Nucleic Acids 
RNA and DNA extracted from samples were dissolved in DEPC-H2O. Concentration was determined by 
spectrophotometry using the NanoDrop spectrophotometer (Thermo Scientific).  
 
 
Microscopy 
Pictures were taken under a Nikon Eclipse E600 fluorescence microscope using a Nikon DS-Ri1 camera 
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RESULTS  
 
Pyrimethamine-resistant parasites were selected after electroporation of schizonts with linearized sub3Δ 
plasmid 
To get a better understanding of the subtilase 3 in malaria parasites we generated a 1111bp deletion in 
the sub3 gene coding sequence of the rodent malaria parasite P. berghei ANKA (Annex III). The 
generated sub3Δ mutants were obtained by electroporation of schizonts with linearized DNA containing 
regions of homology to the sub3 locus, followed by a double crossover event (Figure 3A). Electroporated 
schizonts were injected and allowed to grow in mice 1 and 2. sub3Δ parasites contain only one of the 
residues that make up the catalytic triad, the aspartic acid. Besides lacking the two other residues, a 
histidine and a serine, the mutants are also missing the start codon and the oxyanion hole structure, 
which contributes to the binding affinity of the enzyme.   
A hDHFR selection cassette and its upstream and downstream regulatory elements are present in the 
recombinant locus and confer the sub3Δ parasites resistance to pyrimethamine, an antimalarial drug. 
Uptake and correct integration of the fragment in the genome is a rare event and for this reason the 
proportion of mutants in the population of parasites is extremely low. In order to select the mutant 
parasites, infected mice 1 and 2 were treated with pyrimethamine from day 1p.i. to day 5p.i and 
parasitemia was monitored (Figure 3B). When drug pressure was introduced on day 1p.i. parasitemia 
decreased from 0.5% to a level that it was undetectable by blood smear until day 5 p.i. when 
pyrimethamine treatment was removed. In the absence of drug pressure parasitemia increased over 
time due to the multiplication of parasites that had survived the treatment. 
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Figure 3. Generation and selection of sub3Δ mutants. (A) Schematic representation of the sub3 WT and sub3Δ 
locus. A hDHFR selection cassette (green) confers resistance to pyrimethamine and it is flanked by regions of 
homology (grey) to the sub3 locus. Upstream the hDHFR there is a 726bp fragment of the 5'UTR and downstream a 
668bp fragment of the 3'end of the sub3 coding sequence. The recombinant locus has a 1111bp deletion in the 
sub3 gene. (B) Parasitemia in transfected mice 1 and 2 was monitored daily for 10 days. A pyrimethamine pressure 
period (green box) began on day 1p.i. and it was kept until day 5p.i. 
 
sub3Δ parasites were successfully cloned in mice  
Parasites detected in mice 1 and 2 survived and multiplied in their host after a 5 days-period of selective 
pressure. The presence of pyrimethamine-resistant parasites can be observed due to the generation of 
sub3Δ mutants and\or presence of WT parasites that were able to survive the treatment. The existence 
of recombinant parasites within these populations was confirmed by the presence of a 482bp fragment 
amplified by PCR from a region in the hDHFR cassette (Figure 4A).   
To characterize the sub3Δ mutants a population of 100% recombinant parasites must be obtained. This 
is accomplished by injecting mice with a low number of parasites. The number of parasites and mice to 
be used in the cloning experiment were decided based on the proportion of mutants in the total parasite 
population in infected mice 1 (transfected population 1) and 2 (transfected population 2). The 
enlargement of the recombinant locus due to integration of the hDHFR cassette and presence of 668bp 
of the sub3 coding sequence enables to discriminate the recombinants from the mutants by PCR. 
Primers annealing to the 5' and 3' UTRs of the sub3 locus amplify a fragment of 2563bp in the WT and a 
larger fragment of 3013bp in the mutant. In the transfected population 1 only recombinant DNA was 
detected whereas in transfected population 2 both recombinant and WT DNA was detected (Figure 4B).  
The cloning experiment was performed with blood from mouse 1 by injection of 2 parasites of the 
transfected population 1 per naïve mouse. 
On day 10p.i. 5 of the 10 injected mice were positive for parasites in the blood. To distinguish between 
pure populations - only WT or only mutant -  and mixed populations (WT and mutant) we performed PCRs 
to amplify either the hDHFR cassette or a 626bp fragment of the deleted sub3 coding sequence. 
Amplification of the hDHFR fragment and absence of the sub3 fragment in all populations suggested that 
only recombinant parasites were present in the blood of the infected mice (Figure 4C and 4D).  
To characterize the sub3Δ mutant one clone was chosen and used during the course of all experiments. 
Since we were not able to obtain a WT pure population from the cloning experiment, the parasite strain 
P. berghei ANKA used to generate the mutants was included as the control in all experiments performed 
in this project.   
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Figure 4. Selection of recombinant sub3Δ parasites. (A) Presence of mutants in the transfected populations. 
Amplification of  482bp fragment in the hDHFR cassette in the transfected populations. Genomic DNA from a 
mutant parasite containing the hDHFR cassette integrated in its genome was used as a positive control (first lane); 
WT genomic DNA was used as a negative control (second lane); Water sample - blank (third lane). Amplification of 
the fragment in transfected populations 1 and 2 (fourth and fifth lane). (B) Proportion of mutants in the transfected 
populations. A 2563bp band is amplified from the WT locus in the WT population used as positive control (first lane) 
and in the transfected population 2 (third lane). A 3013bp fragment amplified from the recombinant locus is 
detected in both transfected populations 1 (second lane) and 2 (third lane). (C) Presence of mutants in all the 
cloned positive populations. Detection of a 482bp fragment amplified from the hDHFR cassette in a successfully 
generated mutant containing the hDHFR cassette integrated in its genome (first lane) and in all the cloned positive 
populations (third to seventh lane). Absence of a fragment in the WT population used as a negative control (second 
lane). (D) Absence of WT parasites in all the positive cloned population.  A 626bp fragment amplified from the 
deleted sub3 sequence is amplified in the WT population used as a control (first lane) but not in the positive 
populations (second to sixth lane). T.P.1 – transfected population 1; T.P.2 – transfected population 2 
 
 
The transfected fragment was correctly integrated in the sub3Δ parasites 
Corrected integration of the transfected DNA was tested and confirmed by performing three diagnostic 
PCRs. 5' integration was confirmed by detection of a 1965bp product amplified from the 5'UTR upstream 
the UTR region used for the recombination event and part of the hDHFR cassette. Similarly, 3' integration 
was confirmed by detection of a 982bp product that includes part of the hDHFR cassette and 3'UTR 
downstream the region used for the homologous recombination (Figure 5A). Finally, we  confirmed that 
sub3Δ plasmid was not episomal by absence of a product when primers directed to the hDHFR cassette 
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and to the pDEF-hDHFR transfection plasmid backbone were used (Figure 5B).  Together these results 
show that a sub3Δ mutant was successfully generated.  
 
Figure 5. Correct integration of the transfected DNA in the sub3Δ clone (A) 5' and 3' Integration. Amplification of a 
1965bp fragment (second lane) and a 982bp fragment (fourth lane) in the recombinant clone (fourth lane) was 
detected. A WT population was used as a negative control (first and third lane). (B) Absence of amplification of the 
plasmid backbone discards the hypothesis of episomal presence of the plasmid in the recombinant clone (third 
lane). pDEF-hDHFR plasmid was used as a positive control (first lane) and WT as a negative control (second lane). 
5'INT – 5' integration; 3'INT – 3' integration; Δ – recombinant clone. 
 
 
 
 
sub3 mRNA transcripts were detected in P.berghei ANKA midgut sporozoites 
Knowing the expression profile of a gene is extremely important to speculate on its function. 
Unfortunately, the data available on this matter is not consistent among the different sources. A study 
detected expression both in the sporozoite and blood stages while another study only detected it in the 
sporozoite stage. Here, we report the attempt made to clarify in which stages of P. berghei ANKA WT 
parasites subtilase 3 is expressed. 
We extracted and purified RNA from midguts and salivary glands harvested from infected mosquitoes 
and mixed blood stages purified from whole blood collected from infected mice. The presence of 
messenger RNA (mRNA) obtained by reverse transcription was tested by PCR. In all experiments 
detection of hsp70 transcripts was used as a control since hsp70 gene codes for a heat shock protein 
which is consistently expressed and therefore its transcript must be observed in the analyzed stages.  
There are no introns in sub3 and therefore a control for genomic DNA contamination in the RNA samples 
had to be included in this assay. Only the presence of a PCR product with the expected size amplified 
from the samples of cDNA and its absence in the RNA sample confirms the detection of mRNA of either 
hsp70 or sub3. 
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Data obtained showed that mRNA was detected in the midgut of infected female mosquitoes. A faint 
band can also be seen in infected salivary glands and blood (Figure 6). However, despite the fact that 
this assay was performed multiple times, in salivary glands and blood stages the results were not 
consistent. Infected livers were also examined but hsp70 transcripts were never detected by this 
methodology (not shown). For this reason, we can only affirm with confidence that sub3 transcripts were 
detected in midgut sporozoites.  
 
 
Figure 6. Detection of sub3 transcripts. Expression assays were performed on P.berghei ANKA infected midguts 
(top panels), infected salivary glands (middle panels) and mixed blood stages purified from whole blood of infected 
mice (bottom panels). Primers were used to amplify hsp70 (left panels) or sub3 fragments (right panels). Each 
panel shows a product resulted from amplification of WT genomic DNA used as a PCR positive control (first lane), a 
sample which had water instead of DNA – blank sample (second lane), a product amplified using cDNA made from 
extracted RNA (third lane) and a reaction using only RNA (fourth lane). RT+ - sample of cDNA obtained by reverse 
transcription (RT) ; RT- - sample of the extracted RNA. 
 
 
sub3Δ parasites developed in the mosquito vector 
The part of the life cycle of Plasmodium parasites that takes place in the mosquito is extremely important 
as this is when sexual recombination occurs. Additionally, if multiplication and maturation of sporozoites 
inside the vector is altered it will influence the efficiency of transmission to the mammalian host. To 
characterize the development of the recombinant parasites in this stage Anopheles stephensi 
mosquitoes fed on blood from either sub3Δ or WT infected mice. A total of 5 independent cycles were 
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done and on day 12 post feeding of each cycle we dissected and examined the midguts of female 
mosquitoes (Figure 7A). The use of a GFP expressing strain facilitated the count of the number of oocysts 
per midgut which revealed no difference between the mutants and the controls (Figure 7B).  
On day 15 post feeding of each cycle midguts from female mosquitoes were dissected to determine the 
average number of sporozoites per midgut (Figure 7C). A high variation in this number was observed 
between cycles - varying from 15000 to 78000 in the controls and from 10000 to 66000 in the mutants. 
However, comparison between the two parasites within the same cycle reveals that, except on cycle 3, 
the number of sporozoites per midgut in the WT and in the sub3Δ parasites are similar (Figure 7C). The 
presence of sporozoites in the salivary glands was examined from day 18 to day 21 post feeding after 
dissection of a minimum of 20 female mosquitoes. Although the number of sporozoites was variable its 
presence was always observed (Figure 7D). These results showed that parasite development in the 
vector is not impaired by the deletion in the mutants. Therefore, the data indicate that subtilisin-like 
protease 3 is not required in the gametogenesis process, zygote formation, ookinete development or in 
migration of sporozoites to the salivary glands of the mosquito.   
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Figure 7. sub3Δ sporozoite development in the mosquito. (A) Picture of a midgut dissected from a WT infected 
female mosquito (left panel) and a sub3Δ infected female mosquito (right panel). Because the parasite expresses 
GFP, oocysts are visible in green. Pictures were taken under a fluorescence microscope at 10x magnitude (B) 
Average number of oocysts per midgut in WT infected female mosquitoes (black bar) and sub3Δ infected 
mosquitoes (grey bar) on day 12 post feeding. (C) Average number of sporozoites in the midgut of WT infected 
mosquitoes (black line) and sub3Δ infected mosquitoes (grey line) on day 14 post feeding of each cycle. (D) Table 
of the average number of sporozoites per mosquito present in the salivary glands of WT and sub3Δ infected female 
mosquitoes from day 18 to day 21 post feeding. ND - not determined. 
 
 
 
 
sub3Δ sporozoites glided in vitro 
Sporozoites are highly motile stages that rely on gliding motility to navigate inside of the host. As 
parasites glide they leave a trail of proteins behind, with circumsporozoite protein (CSP) being  the most 
abundant. By using antibodies against this protein we were able to associate a sporozoite to its trail and 
consequently quantify motility of the parasites (Figure 8A). Two independent experiments were 
performed in triplicates. The percentage of gliding was determined by counting the sporozoites that were 
associated with at least one trail in a minimum total of 500 parasites. Only a completed circle is 
considered as one trail. In both experiments sub3Δ parasites glide, in average, 13% less than the control 
(Figure 8B). Moreover, we examined the number of trails that were left by motile sporozoites 
characterizing them in three categories: only 1 trail, 2 to 10 trails and more than 10 trails. The 
distribution of the sporozoites amongst the different categories was similar in both the WT and the 
recombinant parasites, with the majority of the gliding sporozoites being associated with more than 10 
trails in both cases - 60% and 65% respectively. The lowest number of sporozoites belongs to the first 
class (only 1 trail) representing  10% of the parasites in both cases (Figure 8C).  Combined, these data 
suggest that gliding motility is not compromised by the mutation in the sub3 locus.  
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Figure 8. Gliding motility of sub3Δ sporozoites in vitro. (A) Image of WT (left panel) and sub3Δ (right panel) 
sporozoites and trails after incubation with antibody directed to CSP, the most abundant protein in the trail. Trais 
were visualized under a fluorescent microscope at a 40x magnification.  (B) Percentage of WT (black bar) and 
sub3Δ (grey bar) sporozoites that are associated with at least one trail. (C) Percentage of WT and sub3Δ sporozoites 
that are associated with 1 trail (black bar), 2-10 trails (dark grey bar) and more than 10 trails (light grey bar). 
 
 
 
sub3Δ sporozoites were able to traverse hepatocytes in vitro 
 
As previously mentioned sporozoites migrate through cells before invading. During this process, the 
parasites go through the plasma membrane of the host cell, without forming a parasitophorous vacuole. 
The disruption of the host cell membrane is followed by death or survival of the cell, depending on the 
successful resealing of the membrane. To analyze the capacity of sporozoites to migrate through cells we 
used TOTO-1, a high-affinity nucleic acid stain based upon a symmetric cyanine dye dimer that exhibits 
excitation/emission maxima ~514/533 nm when bound to nucleic acids. Therefore, only the cells that 
34 
 
had their membrane disrupted, allowing the access of the dye to the cell, and then resealed, will be 
positive.  
 
The traversal capacity of sub3Δ sporozoites in vitro was assessed by incubating sporozoites with a 
monolayer of hepatocytes in the presence of TOTO-1. Cells in which the nucleus was stained and, 
consequently, showed fluorescence in red were considered positive traversed cells (Figure 9A).  This 
experiment was performed three times in triplicates. Number of traversed cells per 20 fields was 
counted in each triplicate for both the controls and the deletion mutants. The average number of 
traversed cells in the mutants (76) was similar to the controls (84). This result not only supports the 
motility data previously obtained, it also complements it by showing that, when in contact with a 
monolayer of cells, the mutant was able to traverse cells normally (Figure 9B).  
 
 
Figure 9. Migration of sporozoites through hepatocytes. (A) Microscopy images of cells with stained nucleus in red 
after addition of WT sporozoites (left panel) and sub3Δ sporozoites (right panel) in the presence of TOTO-1. Cells 
were visualized under a fluorescence microscope at 40x magnitude (B) Average number of traversed positive cells 
per 20 fields by WT (black bar) and sub3Δ (grey bar) sporozoites.  
 
 
 
sub3Δ parasites invade and multiply inside hepatocytes in vitro 
 
Besides examining the capacity of sporozoites to glide we were also interested in studying the ability of 
the mutant parasites to infect and multiply inside the host cell. In order to do this we carried out an in 
vitro development assay in which either WT or sub3Δ sporozoites were added to a monolayer of human 
hepatoma cells and allowed to multiply for 24h. After that period of time, samples were fixed and GFP 
signal was amplified by immunofluorescence using a monoclonal antibody that recognizes Hsp70. This 
extra step facilitates observation of nuclei and counting of EEFs (Figure 10A). Two independent 
experiments in triplicate were performed and the total number of EEFs per coverslip was counted. On 
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average, 3300 WT and 3100 sub3Δ parasites successfully developed inside the hepatocyte, revealing 
that there was no significant difference between the controls and the recombinant parasites (Figure 
10B). As a consequence of the data presented we can say that neither invasion of cells by sporozoites 
nor their development inside the host cell in vitro was affected by the deletion in the sub3 gene.  
 
 
Figure 10. Parasite development in vitro. (A) Microscopy images of EEFs 24h post infection. WT EEFs are shown on 
the top and sub3Δ EEFs on the bottom. HepG2 nuclei were stained with Hoechst (top and bottom left panels), EEFs' 
GFP signal was amplified by immunofluorescene (top and bottom middle panels) and images of nuclei and EEFs 
were merged (top and bottom right panels). Cells were visualized under a fluorescence microscope at 40X 
magnification (B) Average number of WT (black bar) and sub3Δ (grey bar) EEFs per coverslip 24h post infection of a 
monolayer HepG2 cells with sporozoites. 
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sub3Δ blood stages were detected after sporozoites were injected in mice 
 
Apart from scrutinizing  the properties of sub3Δ parasites in vitro, we examined and characterized the 
capacity of salivary gland sporozoites to infect in vivo. Since P. berghei is used as an experimental mouse 
model it permits the use of mice to conduct in vivo studies. As a first hint to understand if the 
recombinant parasites have their capacity of infecting a host altered, we infected susceptible naïve 
C57BL\6 mice and determined the prepatent period – the number of days that took the parasites to 
become detectable in the blood. A one day difference in the prepatent period indicates an approximately 
10 fold increase or decrease in the infectivity of the parasite depending on if it takes less or more time to 
be detected, respectively.  
 
Four groups of five mice were infected with a certain number of parasites per mouse: 100 WT 
sporozoites (WT100), 100 mutant sporozoites (Δ100), 1000 WT sporozoites (WT1000) and 1000 mutant 
sporozoites (Δ1000). Results demonstrated that, as expected, a 10 fold difference in the number of 
sporozoites injected culminated in a one day difference in the prepatent period. In order to be 
considered positive at least one parasite had to be observed when searching the smear. The data 
collected from the observation of blood smears starting on day 3p.i. showed that in both groups infected 
with 100 sporozoites, parasites were first detected on day 4p.i., although 2 mice in the WT group did not 
become positive after observation of smears until day 10p.i.. In addition, in both groups of mice infected 
with 1000 sporozoites the parasites became detectable one day earlier, on day 3p.i., than the mice 
infected with 100 sporozoites  (Figure 11). Collectively, these data gives evidence that there is no delay 
in the onset of the pathology in the sub3Δ recombinant parasites.  
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Figure 11. Prepatent Period. The day when parasites became detectable in the blood of each mouse was 
determined by blood smear. Four groups of five mice each were respectively injected with 100 WT (WT100) or 
1000 WT sporozoites (WT1000) , 100 (Δ100) or 1000 mutant sporozoites (Δ1000). The presence (+) or absence (-) 
of parasites was recorded. 
 
 
 
 
 
sub3Δ parasites were quantified in the liver upon intravenous and intradermal injection of sporozoites in 
mice 
 
Although the prepatent period in the mutants and the controls is the same, if the difference in infectivity 
between mutant and control was less than 10-fold, it would not be detectable in the previous set of 
experiments. In an attempt to find if that was the case, we conducted a more sensitive experiment. Two 
groups of 5-weeks old female C57BL\6 mice were injected intravenously with WT or sub3Δ sporozoites. 
After 38h.p.i. the parasite burden in the liver was quantified by qPCR. Parasite burden in the liver is 
quantified by the number of copies of parasite 18S ribosomal RNA (rRNA). We observed a similar 
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average number of 18S rRNA copies in both groups of mice, showing that when injected directly in the 
blood, sporozoites reach the liver and develop normally in vivo (Figure 12A).  
 
The following in vivo experiment explored the ability of parasites to reach the liver by their natural route 
of infection, that is, beginning in the dermis. Two groups of five week-old female Swiss Webstar mice 
were infected by i.d. injection with WT or sub3Δ salivary gland sporozoites in the ear. This experiment 
provides further information on the capacity of these parasites to glide in vivo since they must migrate 
from the skin to the liver. I.d. injection of sporozoites contributed to a delay in reaching the liver as well 
as a decrease in the number of parasites that successfully reached the blood. The fact that we used a 
less susceptible host, compared to C57BL\6 mice, contributed, together with the two previous 
observations, to a lower number of copies detected. This experiment was done three times and, along 
with what was previously seen in other stages, recombinant parasites were not affected in their ability to 
reach and develop inside the liver of its host.  
 
 
Figure 12. Quantification of parasite burden in the liver.  (A) Average number of copies of P.berghei 18s risbosomal 
RNA in livers harvested 38h.p.i. from mice infected intravenously with either WT (black bar) or sub3Δ (grey bar) 
salivary gland sporozoites. (B) Average number of copies of P.berghei 18s risbosomal RNA in livers harvested 
38h.p.i. from mice infected intradermaly with either WT (black bar) or sub3Δ (grey bar) salivary gland sporozoites. 
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DISCUSSION and CONCLUSIONS  
 
Plasmodium proteases have been studied for decades  and it has been proven for several of them that 
they play a major role in critical steps of infection such as invasion and egress from the host cell. 
However, there are  no published studies on the parasite subtilisin-like protease 3. Our aim was to get a 
better understanding of the possible role of Sub3 in the Plasmodium life cycle and consequently 
evaluate its potential to be used as a future target for anti-malaria drugs. Here, we characterized a 
mutant parasite in P. berghei which has a deletion in the sub3 gene. We examined the different stages of 
the development of the recombinant parasites, both in the mammalian host and the vector.  
Clues to gene function can often be obtained by examining when and where a gene is expressed in the 
whole organism. Using the previously described methodology, we consistently detected expression of the 
protease in midgut sporozoites indicating that it might be important during this stage. However, 
development and number of midgut sporozoites were not affected in the generated recombinant 
parasite. Regarding the salivary gland sporozoites and blood stages the results were not as consistent. 
This can be explained by  three main arguments. First, the gene is expressed at low levels. In that case, 
detection greatly depends on the parasite burden. This would be a plausible explanation particularly in 
salivary glands sporozoites since the majority of the RNA is extracted from mosquito tissue and debris. 
Therefore,  the amount of parasite RNA that is actually present in the total RNA is extremely low. If the 
gene is expressed at very low levels it might not be detected. To solve this problem, highly infected 
salivary glands must be used to increase the proportion of sporozoite RNA. Concerning the blood stages 
this would not be a strong argument since RNA was extracted from a parasite pellet, meaning there is no 
host RNA involved. Second, the gene expression is tightly regulated. There is the possibility that sub3 
gene is only expressed during a particular(s) stage(s) of the parasite during a blood infection. The 
parasite pellet from which we extract RNA contains mix stages that include rings, trophozoites, schizonts, 
merozoites and gametocytes. The prevalence of each stage in the blood changes with time and if only a 
particular parasite blood stage expresses the gene it might not be detected in a mixed population at a 
particular time point. This event can be avoided by synchronizing a blood culture in which the majority of 
parasites are at the same stage of the development. Third, it is possible that the gene is not expressed 
during these stages. As previously shown, controls for both DNA contamination and presence of parasite 
transcripts (hsp70) were included in all the experiments. Although the controls confirmed that the assay 
worked and it is extremely unlikely that the expression detected is not real, there is the possibility that 
the amplification of a fragment can be due to contamination with genomic DNA.  
One of the most direct ways to find out what a gene – and the protein it encodes - does is to see what 
happens to the organism when that gene is disrupted or deleted.  We examined the consequences of a 
deletion in sub3 gene in P. berghei by analyzing the fitness of the generated deletion parasites in vivo 
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and in vitro. In the mosquito, it was shown that parasite development proceeds normally and by day 18 
post feeding sporozoites are present in the salivary glands. There was no sign of arrest or delay in the 
sub3Δ parasite development at any analyzed phase of its maturation inside the vector.  
In the mammalian host, our main questions were related to the ability of sporozoites to glide and the 
capacity of parasites to successfully invade and develop within the host cell. We performed three assays 
specifically to examine if recombinant salivary gland sporozoites were able to glide and traverse in the 
same way WT sporozoites did. The gliding assay in vitro showed a reproducible 13% reduction in the 
number of motile mutant sporozoites. However, comparison between sub3Δ  and WT motile sporozoites 
demonstrated a similar capacity to glide. It is unlikely that the 13% reduction observed would 
tremendously affect the parasite performance and infectivity in vivo. This theory was supported by the 
fact that sub3Δ and WT sporozoites traversed the same average number of cells when in contact with a 
monolayer of hepatocytes. In addition, results obtained when sporozoites were injected i.d. in mice 
pointed to the same conclusion. Even when injected in the dermis, mutant sporozoites were able to 
successfully reach a blood vessel and initiate infection in the mammalian host. 
Furthermore, recombinant parasites can initiate and grow normally during the liver stage of the life cycle. 
This evidence was verified both in vitro, when sporozoites were added to a monolayer of hepatocytes and 
in vivo, when sporozoites were injected i.v. in the blood circulation of mice. These two assays confirmed 
that the mutation generated did not impair in any significant way neither the ability of sporozoites to 
reach the liver nor their multiplication in the hepatocytes. Moreover, there was no delay in egress from 
the liver as the prepatent period was the same in the mutant and WT parasites – 3 and 4 days when 
1000 and 100 sporozoites are injected, respectively, in mice. Combined, these results consistently 
showed that the recombinant parasites have a normal liver infection. 
We did not perform any specific assays to examine infection during the blood stage. However, there is 
evidence showing that sub3Δ parasites were able to begin and maintain a blood infection. Several 
observations contribute to this affirmation. First, observation of positive blood smears during the 
prepatent assay revealed that liver merozoites must be able to infect erythrocytes and develop in to the 
observed blood stages. Second, smears taken later in the infection show an expected increase in 
parasitemia and all blood stages are present in the infected blood of mice, except for schizonts which are 
rarely observed in unsynchronized blood. Therefore, blood stages merozoites are able to infect 
erythrocytes and there is no obvious arrest of parasite development in the blood. Third, the five cycles 
that were performed using sub3Δ infected mice to infect mosquitoes always resulted in successful 
development of sporozoites in the vector. As previously mentioned, salivary glands are the end result of a 
process that begins with fully developed and functional gametocytes ingested by the mosquito. 
Therefore, this observation shows that differentiation and maturation of recombinant gametocytes 
occurs successfully during a blood infection in the mammalian host. 
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Taking in consideration all the results obtained during the characterization of sub3Δ mutants we can 
affirm with strong confidence that these parasites are able to start and complete every phase of the life 
cycle with no evidence of inferiority in comparison to WT parasites.  
 
 
 
 
 
 
 
 
.  
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FUTURE WORK 
 
The present work showed that in all the performed experiments deletion mutants fitness was not 
affected and therefore, that sub3 deletion did not affect the analyzed stages. Interestingly, there is 
evidence that energy is being spent to assure gene transcription during, at least, one stage of the 
parasite development which suggests otherwise - Subtilase 3 is functionally important. In order to 
continue this study there are three main questions to be addressed: What is sub3 expression profile 
(temporally and spatially)? Is Sub3 important in unanalyzed stages? Is redundancy responsible for a lack 
of phenotype in the sub3Δ mutants?  
 
Regarding the expression of the protease in the WT parasites there are alternatives to the methodology 
used: RT-qPCR which is more sensitive than conventional PCR; the use of a reporter gene which is under 
the control of the same regulatory elements of sub3 and its expression can be monitored by tracking the 
fluorescence or enzymatic activity of its product and, finally, hybridization techniques such as Northern 
analysis and in situ hybridization which reveal when genes are transcribed and in which tissue, and how 
much they produce. By making antibodies directed to Sub3 we can also detect protein expression by 
Western Blot and examine its location in the cell by imunofluorescence assay.  
 
Experimentally, more data need to be collected not only by repeating experiments but also by performing 
different assays. This includes analysis of the capacity of infected mosquitoes to directly initiate infection 
in mice, by mosquito bite. This assay will show if sporozoites are able to leave the salivary glands of the 
mosquito normally. A defect in this process will affect transmission of the parasites to the mammalian 
host. 
 
To answer the third question we will analyze the expression profile of the mutants and assess if there is 
an alteration of the expression pattern of any genes in comparison to WT parasites. Genetic redundancy 
is a term used when a given biochemical function is encoded by two or more genes. In these cases, 
mutations of one of the genes will have a smaller or no effect on the fitness of the organism. Therefore, 
this phenomenon could explain the results previously reported. Putrianti et al., recently showed that two 
serine-type proteases of P.berghei - PbSera1 and PbSera2 - are dispensable during the life cycle. They 
generated single and double gene knockouts and observed that lines progressed normally in vivo. 
However, mutants showed increased expression of PbSera3 – a cysteine protease belonging to the same 
family. This result supports the hypothesis proposed and it raises curiosity to look at expression of 
PbSub1 and PbSub2 in the sub3Δ parasites. 
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ANNEXES 
 
 
Annex I: pDEF-hDHFR Plasmid 
(pUC-18) 
 
 
 
 
 
Annex II: sub3Δ plasmid 
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Annex III: sub3 coding sequence  
 
ATGAAAGAAATGGGAATTAAATATTTGCGATATATGCATATATGGTCTTTAATATATCATGTTTGGAATATAATTCAGTTTATTGATATG
AATGTAATTTATAATAGTTCACCAAATATTATTGAAATTAGCAAAAAAAATGAAATAGAATGGGGAAGGAATAAGGCAAAAATAAGAAT
ATTAAATCAAATAAATAATAAAGAATTGGAAATAAATAAAAATATGAAGATAAATATATATGACATACTTTCCGACAATGATGATATTAAT
TATGAAATAATTATGAAAAAATATTATAAAAATGCAAAGAAAAAAAAATTTAAAATATCTCCAAAAATTCATAGATTAATTATAAGTTTTA
AAAATAATACTTTAAATCATTCCAGTTTTATGAATAAACGATTTATTGACTTGCTTAATTATTGTGGTAAAATAAAAAAATTAGAGCATGT
GAATTTATATCTTTATGATATGGATTCAAATAAGAATGAATTGTTAATAAAGTTTTGTTTATATGCTTTAAAAAATAATAAACAAATTAAT
ATCGAAGCTGATTATAAGGTTAAGCCAATTTACTATAATACATTTTTAAAGAACTACCCCCCCAAAAATTATTATTCTTTACATCCTGAT
GAAAAAAAAAAAAACTTTCAAATAAATAATTCATCTATGTTTAAAAAGCCTTATATAGACTTTAAAAAATATAAAAAAACAAATATTATCG
AAGAACATAATGATATATGTGAACTAGTTAAAGGAACGCAATTGTCTAATCTATATGAAAAAAATAATGTTAATGTTTGTATTATAGACA
CAGGAATAGATTATAATCATCAAAATTTAAAAGAGTCTATAATTGATATGAAATCTACTGAAGGAAATTATCGCCAAAAAAAAAAACAA
AATAATAAATATGATTTTTCTGATATTTCTAACCCAATAGATGGACATGGGCATGGTACATTTATATCTGGAATTATTGCTGGAAATGG
AAACAATATTGATATAAATGACAAAGAAGGAATACAAGGAATAAATAATATGGCAAAATTAATAATTTGTAAAGCTTTAAATAATAATAA
CGTTGGTAATATAAGTGATATATTAGAATGTTTTAATTATTGTACAGAAAAAAATGCAAAAATTATTAATGCAAGTTTTTCTACTAAAAAA
AATTATATTCATTTATATTATGCATTAAAAGAGTTGGAAAAAAAAGAAATTTTAGTTATTACATCTTCAGGAAATTGTGTACAAAAAAAT
GATGAAGGATATAAAGATAACAAAATAAAAACAAATAATAATAAAGAAAAAGATAGTGTTCAAATAAATGGATATACAGAATGTAATAC
AAACTTAATGAAATTATATCCATCTGCTTATTTACCAAATCTAACAAATTTATTAGTTGTTTCTAATATCACTAAAGATTCAAATAATGAT
ATTGTATTATCCAAAGATTCATGTTATAGTAACAAATATGTTAATTTTGGAGCCCAAGGAAATGATATTTTATCGACTCATATTAATAAT
CAATATGCTACAAGTGGCGGTTCATCTTTTTCAGCTGCTGTTGTTACAGGGGTTATTTCATTGTTATTTTCAATAAATCCAAATTTTAAT
AATAATGAAATTATCGAGTTAATTCAAAATGCAATAATACAAACAAATAAATTGAAAGATAAAGTTAAATGGGGAGGGTATTTGAATGT
TTATTTGCTTGTTAATTTAGCTATAGAAAAAATGGGACTTGAATCAAAAATAATTTTTAATGCATAG 
 
Deleted sequence in sub3Δ parasites is colored in green  
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Annex IV: Primer set list 
 
Primer Set Sequence (5' - 3') 
1 
F AAGCTTGAAAATAGATAATTCATATGGAATGTTATG 
R CTGCAGCAAACTATTTACCAATTCACGTCC 
2 
F GGTACCCGTTGGTAATATAAGTGA 
R GAATTCGTCCCATTTTTTCTATAGC 
3 
F CTGCATCGTCGCTGTGTCCC 
R GAACACCTGGGTATTCTGGCAGAAG  
4 
F GAAAATAGATAATTCATATGGAATGTTATG 
R GAATTCGTCCCATTTTTTCTATAGC 
5 
F GACTTGCTTAATTATTGTGG 
R CCTTGTATTCCTTCTTTGTC 
6 
F GGATAGGATGAAGTGATACTTTG 
R GACACAGCGACGATGCAGTTT 
7 
F GTCTCTTCAATGATTCATAAATAGTTGG 
R TAAAACTGGAAACATATACACTTATTG 
8 
F  CTGCATCGTCGCTGTGTCCC 
R GCAGCTGGCACGACAGGTTTC 
9 
F GGAGATTGGTTTTGACGTTTATGTG 
R AAGCATTAAATAAAGCGAATACATCCTTAC 
10 
F TGCAGCAGATAATCAAACTC 
R ACTTCAATTTGTGGAACACC 
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Annex V: Schematic representation of primer set 1-8 target sequence 
